 |
|
|
|
|
|||||||||||||||
 |
|||||||||||||||||||
|
|
|
|
|
|||||||||||||||
|
|||||||||||||||||||
| ;
treatment of ulcerative proctitis and colitis colitis foundation of america crohn's-and colitis foundation of america dealing with ulcerative colitis treatment of colitis ulcerosa compositions and method -fo -treatment of ulcerative colitis detection and treatment of ulcerative colitis method of treating ulcerative colitis method of treating ulcerative colitis with a monoclonal antibody methods for the treatment of ulcerative colitis methods of treating established colitis using antibodies therapeutic agent for ulcerative colitis therapeutic-and-diagnostic-methods for ulcerative colitis and associated disorders treating a patient with ulcerative colitis methods of treatment for ulcerative colitis using aminosalicylate therapeutic agent for ulcerative colitis therapeutic-and-diagnostic-methods for ulcerative colitis and associated disorders treating a patient with ulcerative colitis .
fish oils benefit patients with ulcerative colitis crohn's disease and ulcerative colitis !!!!
|
Ulcerative colitis is a chronic inflammatory bowel disease characterized by inflammation and ulceration of the colon mucosa. Autoimmunity has been suggested as important to the pathogenesis of ulcerative colitis, where the effects are an autoimmune response to cellular antigens. Such cellular antigens may include the tropomyosins. Autoantibodies against tropomyosins are found in sera of individuals with ulcerative colitis and in IgG produced by the cultured lamina propria mononuclear cells that infiltrate inflamed ulcerative colitis tissue. Furthermore, autoantibody to tropomyosin is found in a mouse model for human ulcerative colitis that has been created by targeting deletion of the T-cell receptor ? (TCR?) gene (Mizoguchi et al. 1996. J. Exp. Med. 183:847-856). More recent studies using tropomyosin isoform-specific monoclonal antibodies have demonstrated that colonic epithelial cells synthesize two of the major tropomyosin isoforms, hTM4 and hTM5, whereas colonic smooth muscle cells contain at least he hTM1, hTM2, and hTM3 isoforms (Geng et al. 1998. Gastroenterology 114:912-922). Using recombinant tropomyosin isoforms it was also shown that ulcerative colitis patients produce significant autoantibodies, preferentially against hTM5 (Geng et al. 1998. Gastroenterology 114:912-922; Onuma et al. 2000. Clin. Exp. Immunol. 121:466-471). In fact, 42% of colonic mucosal lymphocytes were committed to production of anti-hTM5 antibody (Onuma et al. 2000. Clin. Exp. Immunol. 121:466-471). In studies in peripheral blood lymphocytes, a T cell response against hTM5 in ulcerative colitis, but not in Crohn's disease, has been demonstrated (Taniguichi et al. 2001. Clin. Immunol. 101:289-295). These data indicate that immune responses, both by B and T cells, are involved in the immunopathogenesis of ulcerative colitis. This is further supported by research showing that hTM5 is expressed on the surface of human colonic epithelial cells but not on small intestine enterocytes, although both colonic and small intestine enterocytes have intracellular hTM5 (Kesari et al. 1999. Clin. Exp. Immunol. 118:219-227; Gneg et al. 1998. Gastroenterology 114:912-922). The mechanism by which hTM5 acts in the pathogenesis of ulcerative colitis remains to be elucidated. An object of the present invention is a composition for treating ulcerative colitis which comprises interferon gamma, TCP-1 gamma and a pharmaceutically acceptable vehicle. Another object of the present invention is a method for decreasing the symptoms of ulcerative colitis in a patient which comprises contacting cells or tissues of a patient with the composition of the present invention, and monitoring the level of TCP-1 gamma gene expression in cells or tissues, wherein an increase in the expression of TCP-1 gamma in said cells or tissues will result in a decrease in the symptoms of ulcerative colitis in said patient. Another object of the present invention is a method for diagnosing ulcerative colitis in a patient which comprises determining a level of TCP-1 gamma in lymphocytes from blood of a patient suspected of having ulcerative colitis; determining a level of TCP-1 gamma in lymphocytes from the blood of several healthy individuals; and comparing the magnitude of the levels of TCP-1 gamma in said patient and said healthy control individuals, wherein a decrease in the magnitude of the level of TCP-1 gamma in the patient as compared to the levels of the healthy control individuals is diagnostic of ulcerative colitis. Yet another object of the present invention is a method for identifying compounds useful for treating ulcerative colitis which comprises harvesting lymphocytes from the blood of patients with ulcerative colitis; determining a first level of TCP-1 gamma in the lymphocytes; contacting the lymphocytes with a compound; and determining a second level of TCP-1 gamma activity in the lymphocytes, wherein the compound is identified as being useful of treating ulcerative colitis if the magnitude of the second level of TCP-1 gamma is greater than the magnitude of the first level of TCP-1 gamma. An object of the present invention is a method for evaluating
efficacy of treatment of ulcerative colitis which comprises determining
a level of TCP-1 gamma in lymphocytes from blood of a patient before administration
of an agent to treat ulcerative colitis; administering to the patient an
agent capable of treating ulcerative colitis; determining a level of TCP-1
gamma in lymphocytes from the blood of the patient after administration
of the agent; and comparing the magnitude of the levels of TCP-1 gamma
in said patient before and after administration of the agent, wherein an
increase in the magnitude of the level of TCP-1 gamma in the patient after
treatment with the agent as compared to the levels of TCP-1 gamma in lymphocytes
before treatment with the agent is indicative of an effective treatment
for ulcerative colitis.
There are also herbal medicines which can very effectively treat colitis
& ulcerative colitis. Boswellia is an
Ayurvedic (Indian traditional medicine) herb, used as a natural alternative
to drugs. Many studies have found that the effectiveness of Boswellia is similar and even superior to sulfasalazine based prescription drugs.
(Source Wikipedia: We recommend taking a
4 months course of our Boswellia Serrata Extract.
Order Boswellia - Shallaki - 4 Months course
Total
of 4 bottles- of Boswellia
- 4 Months course - Taken 2 capusles twice a day.
(All Inclusive) FREE Shipping Worldwide. There are NO ADDITIONAL
CHARGES. Packing & Shipping is absolutely FREE. We will deliver direct
to your door to reach within 12 days from the date of ordering. A signature
will be required at the time of delivery. You can give us your daytime
work address or Post Box address if no one will be present at home to receive
the shipment during daytime.
Please use the form below to mail us for any information. We will revert back within 10 hours .
|
